AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'
By Jeff Overley · March 18, 2019, 11:11 PM EDT
AbbVie Inc.'s colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws, according to a first-of-its-kind suit launched Monday....
To view the full article, register now.